Evidence map›Paper›PMID 39270802›Full record

ArticleThe Journal of allergy and clinical immunology2025

Determinants of persistence and recovery of chronic coronavirus disease 2019 chemosensory dysfunction.

Dante G Minichetti, Amelia Boyd, Evan Lemire, Jonathan Hacker, Adam L Haber, Rachel E Roditi, Mark W Albers, Stella Lee, Kathleen M Buchheit, Tanya M Laidlaw and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Unique and shared patterns of chemosensory dysfunction distinguish chronic COVID-19 and aspirin-exacerbated respiratory disease.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dante G MinichettiDivision of Allergy and Clinical Immunology, Jeff and Penny Vinik Center for Allergic Disease Research, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, Mass.
Amelia BoydDivision of Allergy and Clinical Immunology, Jeff and Penny Vinik Center for Allergic Disease Research, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, Mass.
Evan LemireDepartment of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Mass.
Jonathan HackerDivision of Allergy and Clinical Immunology, Jeff and Penny Vinik Center for Allergic Disease Research, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, Mass.
Adam L HaberDepartment of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Mass.
Rachel E RoditiDivision of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital, Boston, Mass.
Mark W AlbersDepartment of Neurology, Massachusetts General Hospital, Boston, Mass.
Stella LeeDivision of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital, Boston, Mass.
Kathleen M BuchheitDivision of Allergy and Clinical Immunology, Jeff and Penny Vinik Center for Allergic Disease Research, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, Mass.
Tanya M LaidlawDivision of Allergy and Clinical Immunology, Jeff and Penny Vinik Center for Allergic Disease Research, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, Mass.
Lora G BankovaDivision of Allergy and Clinical Immunology, Jeff and Penny Vinik Center for Allergic Disease Research, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, Mass. Electronic address: lbankova@bwh.harvard.edu.

Funding

Therapeutic Control of Aspirin-Exacerbated Respiratory DiseaseU19AI095219 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Joshua A Boyce · 2011 to 2026
$29.1M
Immune dysregulation mechanisms of persistent post-COVID19 olfactory dysfunctionR01DC021425 · NIDCD · BRIGHAM AND WOMEN'S HOSPITAL · PI Lora Bankova · 2024 to 2026
$1.9M
The Role of IL-5 and Local Nasal Polyp Immunoglobulin Production in Aspirin-Exacerbated Respiratory DiseaseK23AI139352 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BUCHHEIT, KATHLEEN MARY · 2019 to 2023
$1.0M
Patient-Oriented Research Mentorship and Training in Upper Airway Allergic and Inflammatory DiseasesK24AI180296 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Tanya Maria Laidlaw · 2024 to 2026
$522k
Allergen-elicited signaling cascades in olfactory microvillous tuft cellsR21AI185057 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BANKOVA, LORA · 2024 to 2025
$476k
Brush cell sensing of aeroallergen-elicited stress signals promotes epithelial cell activationR21AI154345 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BANKOVA, LORA · 2021 to 2022
$437k
NIAID NIH HHS K23 AI139352NIAID NIH HHS K24 AI180296NIAID NIH HHS R21 AI154345NIAID NIH HHS R21 AI185057NIAID NIH HHS U19 AI095219NIDCD NIH HHS R01 DC021425
6 · The paper itself

Abstract

backgroundIn 2% to 4% of patients, coronavirus disease 2019 (COVID-19) chemosensory dysfunction (CSD) persists beyond 6 months, accounting for up to 4 million people in the United States. The predictors of persistence and recovery require further exploration.

objectiveWe sought to define the predictors of recovery and assess the quality of CSD in registry subjects with self-reported persistent smell and taste dysfunction after COVID-19.

methodsCOVID-19 CSD participants (n = 408) from the 4 major waves of the pandemic completed questionnaires at 4 time points between 2021 and 2023, assessing demographics, sinonasal symptoms, and self-assessed recovery. Objective measurements of smell (UPSIT) and taste (BWETT) were performed on a subcohort (n = 108).

resultsIn this chronic CSD cohort, the average symptom duration was 24 ± 5 months, with 70% of those who contracted COVID-19 in 2020 report ongoing dysfunction. Phantosmia and dysgeusia were most prevalent in the early waves of COVID-19, while most participants reported disrupted ability to distinguish scents and flavors as well as undulating chemosensory function. Subjects reported low incidence of subjective sinonasal symptoms but high prevalence of sleep and mood disturbance. Cigarette smoke phantosmia was predictive of persistence of CSD. Conversely, self-reported environmental allergies and hypertension were predictive of recovery, and dust mite allergies specifically were negative predictors of cigarette smoke phantosmia. Finally, no treatment resolved CSD, but nasal steroids were reported to be effective by recovered CSD subjects. Objective measures of both smell and taste were significantly reduced in patients with chronic CSD compared to controls.

conclusionsChronic COVID-19 CSD is a syndrome resistant to standard anti-inflammatory therapy. Preexisting environmental allergies and hypertension predict recovery, while cigarette smoke phantosmia predicts persistence.

Indexed as

COVID-19Olfaction DisordersSARS-CoV-2AdultAgedChronic DiseaseFemaleHumansMaleMiddle AgedRecovery of FunctionSmellSurveys and QuestionnairesTaste DisordersChemosensory dysfunctionCOVID-19smell disruptiontaste disruption

Identifiers

PMID39270802
PMCPMC11700771

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.